EP-2151 Intermediate-risk prostate cancer with EBRT plus permanent 125-I seeds. Long term results. (April 2019) - Peña, M.; Guinot, J.; Roncero, R.; Quiles, B.; Santamaria, P.; Santos, M.A.; Boso, C.; SanchezRelucio, J.C.; Tortajada, M.I.; Arribas, L.